Saturday, October 31, 2026

Gevo Stock Plummets 31% In Last 21 Sessions: What's Causing The Drop?

ViaNews Editorial Team

January 19, 2024

Gevo Stock Plummets 31% In Last 21 Sessions: What's Causing The Drop?

(VIANEWS) - Gevo (NASDAQ:GEVO) shares have fallen 31.97% over 21 sessions from EUR1.22 to EUR0.83, as of 12:23 EST on Friday. This decline followed on the downward trend seen the previous session, while NASDAQ gained 0.64% to EUR15,152.07. Gevo's last closing price of EUR0.85 represents a drop of 63.94% since reaching their 52-week high of EUR2.30.

About Gevo

Gevo, Inc. is a renewable fuels company operating through three segments: Gevo, Agri-Energy and Renewable Natural Gas. The company provides products such as renewable gasoline and diesel; isooctane isobutanol; sustainable aviation fuel; renewable natural gas; isobutylene ethanol and animal feed protein for sustainable aviation travel fueling applications. Founded in 2005 and based out of Englewood Colorado; Methanotech was previously known by this name but rebranded to Gevo Inc in March 2006 when it changed over.

Yearly Analysis

Gevo's stock is trading below its 52-week low, which could indicate it is undervalued. On the other hand, anticipated sales growth is currently estimated at 1311.9% - potentially signifying positive signs for Gevo. EBITDA is not considered an accurate reflection of financial health so other metrics must also be taken into consideration for an in-depth evaluation.

Technical Analysis

Gevo Inc. (GEVO), a renewable fuels company producing biofuels and biochemicals, has seen its share price steadily decline against both its 50-day and 200-day moving averages over recent months, and volume was reported as 46621,360 which represents 17.39% less than its usual volume of 51818,900. Gevo's intraday variation average for the past week, month and quarter were negative 8.13%, negative 2.02% and positive 4.21% respectively; its highest amplitude of average volatility over that time span was 10.46% in any of those three time frames (week, month or quarter). According to the stochastic oscillator, Gevo's stock has reached oversold levels (=20), suggesting it may be time for investors to purchase it. It's important to keep in mind that stock prices may change at any given moment due to many different factors and investors should conduct their own thorough analysis before making investment decisions.

Quarter Analysis

Gevo Inc. has achieved astounding sales growth of 679.8% for this quarter and 10.1% for next. These growth rates are projected to continue with estimated rates of 45.5% this quarter and 14.3% next. In terms of revenue growth, the company has also seen an impressive year-on-year quarterly revenue increase of 1,365.4% year over year over the last twelve months to reach 13.37M. Investors should keep in mind that estimates of growth may differ from actual results and when assessing company performance it is crucial to take other financial metrics, such as profitability and cash flow into consideration.

Equity Analysis

Gevo's revenue growth over the last three years has been negative, falling -31.66% from EUR10.9M to EUR7.3M during that period. ProfitabilityGevo's negative Earnings Per Share (EPS) figure of EUR-0.3 in its trailing twelve month earnings period suggests it lacks profitability while its dependence on single product/customer and commodity price volatility may create additional risks and uncertainties for investors.

More news about Gevo (GEVO).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com